SIGN UP
LOG IN
C
CRMD
Cormedix
9.10
-0.05-0.55%After Hours: 9.00 -0.10 -1.10%19:16 04/25 EDT
OPEN/PREV CLOSE9.02/9.15
TODAY RANGE8.94-9.20
VOL1.44M
MARKET CAP593.15M
52 WEEK RANGE3.610-13.85
AVG VOL (3M)1.44M
% TURNOVER2.20%
TURNOVER--
P/E (TTM)-29.8752
% RANGE2.86%
EPS(TTM)-0.3046
P/E(FORWARD)14.92
P/B6.92
BVPS1.314
DIVIDEND--
P/S13.48
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP549.96M
SHARES OUTSTANDING65.18M
NEXT EARNINGS05/07-05/12
FREE FLOAT60.43M
LOT SIZE1
EX-DIV DATE03/26/2019
News
Press Releases
Financial Reports
Profile
TipRanks·04/11 16:05
Biotech Alert: Searches spiking for these stocks today
TipRanks·04/10 09:16
Positive Outlook and Strong Market Demand Justify Buy Rating for CorMedix
Seeking Alpha·04/09 16:57
3 Biotech Stocks Holding Their Own
TipRanks·04/09 11:27
Truist Financial Remains a Buy on Cormedix (CRMD)
TipRanks·04/08 16:15
CorMedix’s Strong DefenCath Performance and Growth Prospects Justify Buy Rating
Benzinga·04/08 14:37
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday
TipRanks·04/08 14:20
RBC stays bullish on CorMedix as Q1 preliminary revenue reassures on near-term
Dow Jones·04/08 14:14
CorMedix Shares Gain After 1Q Preliminary Sales Beat Views
Dow Jones·04/08 14:02
CorMedix Price Target Maintained With a $15.00/Share by D. Boral Capital
Dow Jones·04/08 14:02
CorMedix Is Maintained at Buy by D. Boral Capital
Benzinga·04/08 13:52
D. Boral Capital Maintains Buy on Cormedix, Maintains $15 Price Target
Seeking Alpha·04/08 12:01
CorMedix expects Q1 sales above estimates, lifts H1 outlook
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.